AXON has identified a novel diseased tau species
which directly correlate with cognitive decline in AD
This new target protein family – Alzheimer's
truncated tau – has been biochemically and
biologically characterized
AXON developed the first transgenic rat models
recapitulating human neurofibrillary degeneration
of AD
Diseased Alzheimer's truncated tau represents
Axon’s prime drug target
